Addex Therapeutics

Addex Therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including G-Protein Coupled Receptors (GPCRs), receptor tyrosine kinases (RTKs) and cytokine receptors, such as the TNF receptor superfamily. Many such targets have been widely recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery.

The Company’s two lead products are being investigated in three Phase IIa clinical studies: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc., to treat schizophrenia and anxiety. Addex also is advancing several preclinical programs including: GABA-BR PAM for overactive bladder and other disorders; mGluR4 PAM for Parkinson's, MS and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and depression. In addition, Addex has discovery programs to identify allosteric modulators including TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer’s, Parkinson’s and Huntington’s diseases) TNFR1 NAM for inflammation (e.g. rheumatoid arthritis) and other diseases.